Showing 4221-4230 of 8607 results for "".
- Researchers Identify Protein that Helps Melanoma Spread Throughout the Bodyhttps://practicaldermatology.com/news/researchers-identify-protein-that-helps-melanoma-spread-throughout-the-body/2461495/Research led by Queen Mary University of London, King’s College London and the Francis Crick Institute has identified a protein that makes melanoma more aggressive by giving cancer cells the ability to change the shape of their nucleus–a characteristic which allows the cells to migrat
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- FDA Grants Fast Track Designation for Union’s Oral Orismilast for Moderate to Severe HShttps://practicaldermatology.com/news/fda-grants-fast-track-designation-for-unions-oral-orismilast-for-the-treatment-of-moderate-to-severe-hs/2461493/The US Food and Drug Administration (FDA) has granted Fast Track designation to oral orismilast for the treatment of moderate to severe hidradenitis suppurativa (HS). The FDA's Fast Track designation is intended to facilitate the development and review of drug candidates that treat
- Study Reveals Novel Insights on Melanin Formationhttps://practicaldermatology.com/news/study-reveals-novel-insights-on-melanin-formation/2461491/“Nrf3” regulates the process of melanin production in mouse and human cells, a new study shows. NF-E2-related factor 3 or “Nrf3,” a known transcription factor, or protein involved in the pro
- Topline Results: Union's Oral Orismilast Improves PASI by Week 16 in Patients with Moderate to Severe PsOhttps://practicaldermatology.com/news/topline-results-unions-oral-orismilast-improves-pasi-by-week-16-in-patients-with-moderate-to-severe-pso/2461489/Oral orismilast performed well in adult patients with moderate to severe psoriasis, according to topline results from the IASOS Phase 2b study. Data from the 202 patients randomized and dosed in the study showed that all active arms of oral orismilast achieved the primary endp
- Regenerative Medicine in Action: Scars Faded Using Transplanted Hair Follicleshttps://practicaldermatology.com/news/regenerative-medicine-in-action-scars-faded-using-transplanted-hair-follicles/2461486/Skin scars began to behave more like uninjured skin after they were treated with hair follicle transplants in a small new study. The scarred skin harboured new cells and blood vessels, remodelled collagen to restore healthy patterns, and even expressed genes found in healthy unscarred s
- Coming Soon? The first FDA-approved Topical Prescription Product for Molluscumhttps://practicaldermatology.com/news/coming-soon-the-first-fda-approved-topical-prescription-product-for-molluscum/2461485/Ligand Pharmaceuticals Inc.’s partner Novan submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum. Assuming the filing is accepted b
- Apyx Medical Launches #ThisIsMe Campaign for Renuvionhttps://practicaldermatology.com/news/apyx-medical-launches-thisisme-campaign-for-renuvion/2461478/Apyx Medical Corporation is rolling out its first-ever direct-to-consumer brand campaign for Renuvion, a proprietary helium plasma and radiofrequency technology. The #ThisIsMe campaign is aimed at U.S. consumers who are interested in a minimally invas
- Practical Dermatology® Magazine’s Sister Publication Named Exclusive Media Partner for Octane’s Aesthetics Tech Forum 2023https://practicaldermatology.com/news/practical-dermatology-magazines-sister-publication-named-exclusive-media-partner-for-octanes-aesthetics-tech-forum-2023/2461474/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is the exclusive media partner for Octane’s Aesthetics Tech Forum 2023.Now in its fourth year, Octane's Aesthetics Tech Forum is a two-day immersive, in-person and digital
- Journey Medical Corporation Shares Positive Comparative Pharmacokinetic Data for DFD-29 for Rosaceahttps://practicaldermatology.com/news/journey-medical-corporation-shares-positive-comparative-pharmacokinetic-data-for-dfd-29-for-rosacea/2461473/Journey Medical Corporation shared positive PK comparability data of DFD-29 and key updates on the progress of its pivotal Phase 3 clinical study of DFD-29 for the treatment of papulopustular rosacea in collaboration with Dr. Reddy’s Laboratories Ltd. The PK study was designed as